RT Journal Article
SR Electronic
T1 CC- chemokine ligand 25 mediates inflammatory crosstalk between adipose and liver in non-alcoholic fatty liver disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.26.21261056
DO 10.1101/2021.07.26.21261056
A1 Richard Parker
A1 J Drake
A1 CJ Weston
A1 DH Adams
YR 2021
UL http://medrxiv.org/content/early/2021/07/28/2021.07.26.21261056.abstract
AB Background and Aims Obesity is closely associated with non-alcoholic fatty liver disease (NAFLD). We investigated expression of the CC-chemokine CCL25 in adipose tissue (AT) and its relation to hepatic inflammation.Methods Primary human tissue was used for all experiments. CCL25 concentration in serum was measured with enzyme-linked immunosorbent assay (ELISA). Gene expression of CCL25 was measured with polymerase chain reaction. Protein expression was assessed with ELISA and immunohistochemistry. Leukocyte trafficking was investigated in a dynamic assay to model the hepatic sinusoid. Expression of CCR9 on liver-infiltrating leukocytes analysed with flow cytometry.Results Circulating CCL25 was increased in obesity. Gene expression of CCL25 in AT was several-fold higher than in liver, although protein levels of CCL25 were comparable. Soluble CCL25 in flow media increased leukocyte trafficking across hepatic endothelium. Greater numbers of CCR9+ cells were seen in liver tissue from patients with NAFLD, where the greatest difference was in the number of CD14+CD16+ monocytes.Conclusions CCL25 and its cognate receptor CCR9 mediate a novel pathway of inflammatory crosstalk between adipose and liver tissue in NAFLD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a Young Investigators grant from the European Association for the Study of the Liver (EASL)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Samples of human liver tissue for isolation and culture of endothelial cells, gene expression analysis and immunohistochemistry were collected with the approval of Birmingham Research Ethics Committee (reference 06/Q2708/11). Plasma for measurement of CCL25 in human blood was obtained from the Human BioResource Centre (HBRC) at the University of Birmingham. The HBRC is licensed under the UK Human Tissue act (HTA) (licence 12358). It has research ethics committee (REC) approval to collect and distribute samples and data (North West REC, reference 15/NW/0079).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are not publicly available but can sharing of anonymised experimental data can be discussed with the corresponding author